FS Bancorp, Inc. Authorizes Additional Share Repurchases
MOUNTLAKE TERRACE, Wash., Nov. 15, 2024 (GLOBE NEWSWIRE) — FS Bancorp, Inc. (NASDAQ: FSBW) (“Company”), the holding company for 1st […]
IDT Corporation to Participate in Southwest IDEAS Investor Conference
NEWARK, NJ, Nov. 15, 2024 (GLOBE NEWSWIRE) — IDT Corporation (NYSE: IDT), a global provider of fintech, cloud communications, and […]
H&E Rentals Reports Quarterly Cash Dividend
BATON ROUGE, La., Nov. 15, 2024 (GLOBE NEWSWIRE) — H&E Equipment Services, Inc. (NASDAQ: HEES) (“H&E”, the “Company”, d/b/a “H&E […]
Ranchero Announces Debt Settlement Transaction
VANCOUVER, British Columbia, Nov. 15, 2024 (GLOBE NEWSWIRE) — Ranchero Gold Corp. (“Ranchero” or the “Company”) (TSX.V:RNCH) is pleased to […]
From One Truck to Industry Titan: Saia LTL Freight Celebrates 100 Years
JOHNS CREEK, Ga., Nov. 15, 2024 (GLOBE NEWSWIRE) — This year, Saia Inc. (NASDAQ: SAIA) proudly celebrates Saia LTL Freight’s […]
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Eight participants achieved HBsAg loss at any time. Two participants met criteria for functional cure. Two participants who discontinued NUC […]
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the […]
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit […]
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the […]
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
— Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of […]
